From the past decades, various diagnostic techniques had been used for the detection of various chronic diseases. From Ancient time, the diagnosis of genetic diseases is a major concern since there were few diagnostic techniques available in the market. Instead, diagnosis was possible only when the disease showed the symptoms as most genetic diseases are hereditary and hence can be observed only when found in their children. Therefore, scientists tried to find out the less invasive techniques and found In Vitro Diagnostic (IVD) method. It uses only blood or tissue from the patients and hence reduces the susceptibility for other diseases. After the diagnosis was done using this technique, it was found that the genetic diseases are mainly due to genetic imbalance or molecular imbalance. And hence scientists tried to found new technique which is specific only for genes or molecules related to that particular disease, resulted in the emergence of molecular cytogenetics. It helps to find the cause of disease at molecular or cellular level. “Meticulous Research” in its latest publication states that, the “global market for molecular cytogenetics is expected to grow at a CAGR of 11.0% from 2017 to 2022 to reach $2,266.4 million by 2022.”
Download free sample report: https://www.meticulousresearch.com/download-sample-report/?cp_id=3067
This growth is primarily driven by the increasing focus on preventive healthcare measures, increasing genetic abnormalities; growing aging population and subsequent increase in chronic diseases, increasing need to reduce mounting healthcare cost, and rising focus on clinical and research diagnosis.
The focus on preventive healthcare measures has been continuously increasing since past decade. This is mainly due to the increase in rare and genetic diseases across the world. According to the Global Genes statistics, there are about 7,000 rare diseases, out of which around 80% are of genetic origin and remain undiagnosed until 2017. There are about 350 million people affected by genetic and rare diseases in 2017 across the world. Hence, the preventive measures become an important domain in healthcare system. The preventive measures can be acquired by identifying the most promising preventing care technologies. Preventive healthcare measures can be used in form preventive tests so as to identify the current disease status of the patient. This is widely used because it determines whether the person has positive history of symptoms or showing risk of disease at a future date.
With continuous rise in the number of people affected by genetic diseases, there is lot of momentum for the preventive tests across the globe. According to World Health Organization (WHO), the preventive measures can be demonstrated by considering the Levels of prevention, Stages in the Natural History of Disease and Modes of intervention. The levels of prevention and modes of intervention make the market to grow up. The preventive measures for the genetic diseases can be considered for establishing the diagnosis of hereditary diseases, predict the probability of genetic diseases in individuals or in family, measuring clinical expression of diseases, predicting the birth of an offspring with or without genetic diseases using sophisticated molecular cytogenetics techniques.
Also, it also reduces the downstream processing costs, lowering hospitalization rate, enabling minimally invasive procedures. This trend significantly contributes to improve the health of people which in turn increase the availability of molecular and cytogenetic diagnostic products around the world.
The report provides meticulous analysis of Molecular Cytogenetics Market on the basis of technique (fluorescence in situ hybridization, comparative genomic hybridization, in situ hybridization, karyotyping, and banding techniques), product (instruments, kits and reagents, software, services, and consumable/accessories), application (oncology, genetic disorders, personalized medicines, and other), end user (pharmaceuticals and biotechnological companies, clinical and diagnostic laboratories, and academic institutes), and geography.
The key players analyzed in the molecular cytogenetics market are Thermo Fisher Scientific (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer (U.S.), Bio-Rad Laboratories (U.S.), Applied Spectral Imaging (U.S.), Quest Diagnostics (U.S.), Roche Diagnostics (Switzerland) , Danaher Corporation (U.S.), Illumina (U.S.), and Oxford Gene Technology (U.S.).
For detailed Table of Content; Download free sample report here